Screening potential COVID-19 drug therapies through lung organoids promises a faster pipeline to approved treatments.
With an estimated 44 million diagnosed with Alzheimer’s disease worldwide, research is moving quickly to better understand the disease.
In this episode of the Newton Series, Katie Pollard shares how big data allows for deep exploration of the human microbiome.
1650 Owens Street, San Francisco, CA 94158 email@example.com 415.734.2000
© 2020 Gladstone Institutes All Rights Reserved Terms and Conditions Conflict of Interest
Careers For Media Contact
Find Out More